

# REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

*Syman et al*

Application Number

08/162407

Filed

12/3/93

Group Art Unit

1806

Examiner

*Spector*

Paper No. 13

Assistant Commissioner for Patents  
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☐ (A) referred to in United States Patent Number 5554512, column \_\_\_\_\_
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, on page \_\_\_\_\_ of paper number \_\_\_\_\_
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. \_\_\_\_\_, filed \_\_\_\_\_, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

*Shari Hall*  
\_\_\_\_\_  
Signature  
*Shari Hall*  
\_\_\_\_\_  
Typed or printed name

12/10/97  
\_\_\_\_\_  
Date

FOR PTO USE ONLY

Approved by *[Signature]*  
\_\_\_\_\_  
LSO 1 (Initials)

Unit: PRR



US005554512A

**United States Patent** [19]

Lyman et al.

[11] Patent Number: 5,554,512

[45] Date of Patent: Sep. 10, 1996

[54] **LIGANDS FOR FLT3 RECEPTORS**[75] Inventors: Stewart D. Lyman, Seattle; M.  
Patricia Beckmann, Poulsbo, both of  
Wash.

[73] Assignee: Immunex Corporation

[21] Appl. No.: 243,545

[22] Filed: May 11, 1994

**Related U.S. Application Data**[63] Continuation-in-part of Ser. No. 209,502, Mar. 7, 1994,  
abandoned, which is a continuation-in-part of Ser. No.  
162,407, Dec. 3, 1993, abandoned, which is a continuation-  
in-part of Ser. No. 111,758, Aug. 25, 1993, abandoned,  
which is a continuation-in-part of Ser. No. 106,463, Aug. 12,  
1993, abandoned, which is a continuation-in-part of Ser. No.  
68,394, May 24, 1993, abandoned.[51] Int. Cl.<sup>6</sup> ..... C12N 15/19; C07H 21/04[52] U.S. Cl. .... 435/69.5; 435/69.1; 435/172.1;  
435/240.2; 435/252.3; 435/320.1; 530/351;  
530/399; 536/23.5; 935/13; 424/85.1[58] Field of Search ..... 536/23.5; 530/350,  
530/351, 399; 435/69.1, 69.5, 69, 7, 240.2,  
320.1, 172.1, 252.3; 935/13; 424/85.1[56] **References Cited****U.S. PATENT DOCUMENTS**

5,185,438 2/1993 Lemischka ..... 536/23.2

**OTHER PUBLICATIONS**

J. G. Flanagan et al. Cell 63:185-194, 1990.

O. Rosnet et al. Oncogene 6:1641-1650, Sep. 1991.

*Primary Examiner*—Stephen G. Walsh*Assistant Examiner*—Lorraine M. Spector*Attorney, Agent, or Firm*—Stephen L. Malaska[57] **ABSTRACT**

Ligands for  $\text{flt3}$  receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to  $\text{flt3-L}$  as an isolated protein; the DNA encoding the  $\text{flt3-L}$ , host cells transfected with cDNAs encoding  $\text{flt3-L}$ , compositions comprising  $\text{flt3-L}$ , methods of improving gene transfer to a mammal using  $\text{flt3-L}$ , and methods of improving transplantations using  $\text{flt3-L}$ .  $\text{Flt3-L}$  finds use in treating patients with anemia, AIDS and various cancers.

**21 Claims, No Drawings**